View all CSAC CME

Share a PER® activity with your colleagues or friends. Connect with the PER® social network.



Accreditation/ Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Resources

PER Pulse™ Recaps highlight key points presented in Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of Breast Cancer. The first and second PER Pulse™ Recaps focus on data from phase III trials of a 3-drug, rolapitant-containing regimen for CINV control in women receiving chemotherapy for breast and gynecologic cancers, respectively. The third PER Pulse™ Recap focuses on results of a phase III study that compared dexamethasone on day 1 versus on days 1, 2, and 3, as part of a triple-drug CINV regimen for patients receiving cisplatin or anthracycline-cyclosphosphamide chemotherapy.


Acknowledgment of Commercial Support

This activity is supported by an educational grant from Tesaro.


Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment and Management of CINV


Release Date: July 26, 2016
Expiration Date: July 26, 2017
Media: Internet - based

Activity Overview

This activity is designed to update physicians on the data that has been recently presented at major cancer conferences so they can assess and prepare to apply these findings to their clinical practice to improve patient care.

CME Activity Table of Contents

  • Rolapitant for Prevention of CINV in Patients With Breast and Gynecologic Cancers
  • Phase II Study of Olanzapine 10 mg Versus 5 mg for Cisplatin-Induced Emesis
  • Phase III Study of a NK1 Receptor Antagonist Plus Palonosetron With Dexamethasone on Day 1 or Days 1-3 for Highly Emetogenic Chemotherapy
  • Ginger for Prevention of CINV Associated With Adriamycin-Cyclophosphamide
  • Practice Patterns and Adherence to Antiemesis Guidelines: Results of a Survey of Oncology Nurses
  • APF350 Versus Ondansetron With Fosaprepitant Plus Dexamethasone for CINV Induced by Highly Emetogenic Chemotherapy: Exploratory Age and Gender Subgroup Analyses of Data From the Phase III MAGIC Trial

 

Instructions For This Activity & Receiving Credit

  • You will need to login to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review videos/content until you finish the presentation.
  • At the end of the activity, "educational content/video" will be available for your reference.
  • In order to receive a CME certificate, participants must complete the activity.
  • Complete the posttest and pass with a score of 70% or higher, complete the evaluation and then click on request for credit. Participants may immediately download a CME certificate upon completion of these steps.


Target Audience

This educational program is directed toward medical oncologists, nurse practitioners, physician assistants, and nurses. Other healthcare professionals involved in the treatment and management of patients with CINV are also invited to participate.

Educational Objectives

At the conclusion of this activity, participants should be better prepared to:
  • Discuss clinical trial designs and endpoints of noteworthy trials evaluating novel strategies for the management of CINV
  • Assess the effectiveness of emerging antiemetic strategies for CINV in the context of evolving treatment standards in the field
  • Place into clinical context emerging evidence concerning novel approaches to manage CINV
  • Apply clinical trial evidence to practically manage real-world clinical scenarios in the management of breakthrough symptoms, delayed CINV, nausea, and antiemetic regimens for multi-day chemotherapy

Faculty, Staff, and Planners' Disclosures

Faculty

Richard J. Gralla, MD, FACP
Professor of Medicine
Albert Einstein College of Medicine
Jacobi Medical Center
Bronx, New York
Disclosure: Consultant: Merck, Heron, Helsinn, Tesaro
 

Eric Roeland, MD
Director of Clinical Research in Symptom Intervention
Assistant Clinical Professor of Medicine
UC San Diego Health - La Jolla
La Jolla, CA
Disclosure: Consultant: Helsinn, Heron; Speaker's Bureau: Helsinn, Eisai, Teva.

The following individuals have no relevant financial relationships with commercial interests:
The staff of PER®, LLC.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

It is the policy of Physicians' Education Resource®, LLC, (PER®) to ensure fair balance, independence, objectivity, and scientific rigor in all of our CME activities. In accordance with ACCME guidelines, PER® requires everyone who is in a position to control the content of an educational activity, including spouses/partners, to disclose all relevant financial relationships with any commercial interest to participants as a part of the activity planning process. PER® has implemented mechanisms to identify and resolve all conflicts of interest prior to release of this activity.

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only, and is not meant to substitute for the independent medical judgment of a physician or nurse relative to diagnostic, treatment, or management options for a specific patient's medical condition.

The opinions expressed in the content are solely those of the individual faculty members, and do not reflect those of Physicians' Education Resource®, LLC, or any of the companies that provided commercial support for this activity.

Hardware And Software Requirements

Supported Browsers
Internet Explorer v.7 or greater (for Windows) | Mozilla Firefox v.2 or greater (for Windows, Mac, Linux)

Minimum System Requirements (Windows)
  • A Pentium-based PC or compatible computer
  • At least 64MB of RAM
  • Windows 95/98/NT/ME/2000/XP/Vista system software
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise
Minimum System Requirements (Mac OS)
  • A PowerPC processor-based Macintosh computer
  • At least 64MB of RAM
  • Mac OS 7.5 or later
  • Screen resolution of 1024 x 786 or larger recommended
  • PDF Reader: Adobe Reader 5.0 or higher, Foxit Reader 2.0 or likewise




Calendar of Events
SUNMONTUESWEDTHURSFRISAT
 123456
78910111213
14151617181920
21222324252627
28293031
Filter By